AGNG

EBIZ seeks to invest in companies positioned to benefit from the increased adoption of E-commerce as a distribution model, including those operating E-commerce platforms, providing E-commerce software and services, and selling goods and services online.

GNOM seeks to invest in companies that stand to benefit from further advances in the field of genomic science, including those involved in gene editing, genomic sequencing, genetic medicine and therapy, computational genomics, and biotechnology.

MILN seeks to invest in companies positioned to benefit from the rising spending power and unique preferences of the U.S. Millennial generation, spanning categories such as social media and entertainment, food and dining, apparel, health and fitness, travel, housing, and financial services.

AGNG can complement traditional health care allocations by delivering targeted exposure to companies positioned to serve the world's expanding senior population, rather than broad pharmaceutical or health care conglomerates.

The fund can help capture growth catalysts from investigational treatments targeting age-related conditions such as Alzheimer's disease to new research in the world of oncology, where large addressable markets and a historical lack of effective therapies are converging to create significant opportunity.

Humans are living longer than ever, with forecasts suggesting the global population of adults 65 and older could double to 1.7B by 2053.¹

Older individuals, those 65 and older, make up 17% of the U.S. population and account for 37% of healthcare spending.^2,3 Nearly 70% of adults 65 and older will require long-term care in their lifetime.⁴

The Aging Population theme is a global trend, affecting a wide range of industries. AGNG invests accordingly, offering exposure to companies regardless of sector or geographic classification.

¹United Nations, Jul 2024

²Ibid
³Centers for Medicare & Medicaid Services, Sep 2024
⁴U.S. Department of Health and Human Services, Office of Disability Aging and Long-Term Care Policy, and Urban Institute, Apr 2019

Related Product Research

The financial statements include the Fund's disclosures required by Items 7 through 11 of Form N-CSR, which includes the financial statements, financial highlights, and other important information when applicable.

The financial statements include the Fund's disclosures required by Items 7 through 11 of Form N-CSR, which includes the financial statements, financial highlights, and other important information when applicable.

Drug development is key to pharmaceutical industry success, and it’s crucial for investors to understand a drug’s lifecycle to navigate this dynamic sector.

Several promising drugs may be approved in 2024, which could provide Eli Lilly, Moderna, and Bristol Myers Squibb with potentially attractive growth catalysts.

The Premium/Discount chart demonstrates the difference between the daily market price of shares of the Fund and the Fund's net asset value (NAV). The vertical axis of the chart shows the premium or discount of the daily market price as a percentage of the NAV. The horizontal axis shows each trading day in the time period, and each data point in the chart represents the Premium/Discount on that day. The data presented in the chart and table above represent past performance and cannot be used to predict future results.

The primary explanation is that timing discrepancies can arise between the NAV and the trading price of the Fund. Since shares of the Fund trade on the open market, prices are affected by the constant flow of information received by investors, corporations and financial institutions. Depending on how this changing information affects investor sentiment, shares of the Fund may deviate slightly from the value of the Fund's underlying assets. The NAV of the Fund is only calculated once a day (normally at 4:00 p.m. eastern time). As a result, shareholders may pay more than NAV when they buy Fund shares and receive less than NAV when they sell those shares, because shares are purchased and sold at current market prices. However, due to the creation and redemption process that is unique to ETFs, market makers are able to minimize these deviations from NAV by taking advantage of arbitrage opportunities.

Close of Trading Times. Although both the NAV and the daily market price of the Fund are generally calculated based on prices at the closing time of the exchange (generally 4:00 p.m. eastern time), slight differences in this timing may cause discrepancies.

Time of Last Trade. Trading of Global X funds generally takes place during normal trading hours (9:30 a.m. to 4:00 p.m. eastern time). However, it is important to note that the last trade - from which the closing price is determined - may not occur at exactly 4:00 p.m. eastern time. Therefore, changing market sentiment during the time difference may cause the NAV to deviate from the closing price.

International Holdings. The premiums and discounts for funds with significant holdings in international markets may be less accurate due to the different closing times of various international markets. Because the Funds trade during U.S. market hours while the underlying securities may not, the time lapse between the markets can result in differences between the NAV and the trading price.

Source: AltaVista Research, LLC